{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:53:01Z","timestamp":1790801581841,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clinthera.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T21:33:53Z","timestamp":1723584833000},"page":"733-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis"],"prefix":"10.1016","volume":"46","author":[{"given":"Yuli","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza M.","family":"Raymundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Unnebrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gweneth F.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique D.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvina D.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Zinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-2025","authenticated-orcid":false,"given":"Mohamed-Eslam F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.07.003_bib0001","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health","volume":"131","author":"Shaw","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the national eczema association","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0003","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0004","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2500\/aap.2018.39.4175","article-title":"The burden of atopic dermatitis","volume":"39","author":"Reed","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0005","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2006.01047.x","article-title":"Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema","volume":"60","author":"Lewis-Jones","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0006","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2021.02.069","article-title":"Association of pediatric atopic dermatitis and psoriasis with school absenteeism and parental work absenteeism: a cross-sectional United States population-based study","volume":"85","author":"Cheng","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0007","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/pai.12095","article-title":"Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization","volume":"24","author":"Silverberg","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0008","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council","volume":"77","author":"Simpson","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0009","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0010","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0011","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"Supplementary Material","key":"10.1016\/j.clinthera.2024.07.003_bib0012","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0013","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0014","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","article-title":"Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication","volume":"59","author":"Mohamed","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0015","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcph.1550","article-title":"Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis, Crohn's disease, ulcerative colitis, or atopic dermatitis: population analyses of phase 1 and 2 clinical trials","volume":"60","author":"Nader","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0016","doi-asserted-by":"crossref","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0017","unstructured":"AbbVie Inc. RINVOQ\u2122 (Upadacitinib) [US Package Insert] North Chicago, IL. AbbVie Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218347s000lbl.pdf.2019."},{"key":"10.1016\/j.clinthera.2024.07.003_bib0018","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1111\/bcp.15803","article-title":"Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis","volume":"89","author":"Ismail","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0019","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-019-00739-3","article-title":"Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials","volume":"58","author":"Kl\u00fcnder","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"60","author":"Hanifin","year":"1980","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0021","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cpdd.844","article-title":"Characterization of the effect of upadacitinib on the pharmacokinetics of bupropion, a sensitive cytochrome P450 2B6 probe substrate","volume":"10","author":"Mohamed","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clinthera.2024.07.003_bib26","unstructured":"FDA. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Reviews for RINVOQ (Application Number 211675Orig1s000). 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211675Orig1s000ClinPharmR.pdf Accessed 5 August 2024."},{"key":"10.1016\/j.clinthera.2024.07.003_bib0022","first-page":"666","article-title":"Pharmacokinetics of Upadacitinib in Pediatric Patients with Polyarticular Course Juvenile Idiopathic Arthritis","volume":"82","author":"Qian","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0023","first-page":"S5","article-title":"Extrapolation approach for upadacitinib in juvenile idiopathic arthritis leveraging pharmacokinetics, exposure-response, and real-world patient data","volume":"115","author":"Qian","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0024","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.clinthera.2024.07.003_bib0025","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","article-title":"Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and ad up randomized clinical trials","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T02:50:24Z","timestamp":1730343024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0149291824002005"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.07.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}